Bright renoprotective properties of metformin: Beyond blood glucose regulatory effects

Iranian Journal of Kidney Diseases

Volumn 7, Issue 6, 2013, Pages 423-428

  Nasri, Hamid ^a   Baradaran, Azar ^a   Ardalan, Mohammad Reza ^b   Mardani, Saeed ^c   Momeni, Ali ^c   Rafieian Kopaei, Mahmoud ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetic nephropathy; Metformin; Oxidative stress

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; METFORMIN; REACTIVE OXYGEN METABOLITE; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ALBUMINURIA; APOPTOSIS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; KIDNEY STRUCTURE; KIDNEY TUBULE; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; RENAL PROTECTION; REVIEW; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; RAT;

ALBUMINURIA; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HYPOGLYCEMIC AGENTS; METFORMIN; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES;

EID: 84887831584     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton). 2010;15:412-8.
2. Cuny T, Guerci B, Cariou B. New avenues for the pharmacological management of type 2 diabetes: An update. Ann Endocrinol (Paris). 2012;73:459-68.
3. Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine. 2012.
4. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-9.
5. Nasri H. On the occasion of the world diabetes day 2013; diabetes education and prevention; a nephrology point of view. J Ren Inj Prev. 2013;2:31-2.
6. Ouslimani N, Peynet J, Bonnefont-Rousselot D, Therond P, Legrand A, Beaudeux JL. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism. 2005;54:829-34.
7. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-74.
8. Solati M, Mahboobi H. Paraoxonase enzyme activity and dyslipidemia in chronic renal failure patients. J Nephropathol. 2012;1:123-5.
9. Gallo A, Ceolotto G, Pinton P, et al. Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes. 2005;54:1123-31.
10. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-14.
11. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008;5:157-67.
12. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29:6S28-35.
13. Sahni N, Gupta K. Dietary antioxidants and oxidative stress in predialysis chronic kidney patients. J Nephropathol. 2012;1:134-42.
14. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063-9.
15. Khajehdehi P. Turmeric: Reemerging of a neglected Asian traditional remedy. J Nephropathol. 2012;1:17-22.
16. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab. 2003;29:6S71-6.
17. Detaille D, Guigas B, Chauvin C, et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54:2179-87.
18. Sung JY, Choi HC. Metformin-induced AMP-activated protein kinase activation regulates phenylephrinemediated contraction of rat aorta. Biochem Biophys Res Commun. 2012;421:599-604.
19. Rosen P, Wiernsperger NF. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab Res Rev. 2006;22:323-30.
20. Seo-Mayer PW, Thulin G, Zhang L, et al. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am J Physiol Renal Physiol. 2011;301:F1346-57.
21. Zorov DB. Amelioration of aminoglycoside nephrotoxicity requires protection of renal mitochondria. Kidney Int. 2010;77:841-3.
22. Zorov DB, Krasnikov BF, Kuzminova AE, Vysokikh M, Zorova LD. Mitochondria revisited. Alternative functions of mitochondria. Biosci Rep. 1997;17:507-20.
23. Plotnikov EY, Kazachenko AV, Vyssokikh MY, et al. The role of mitochondria in oxidative and nitrosative stress during ischemia/reperfusion in the rat kidney. Kidney Int. 2007;72:1493-502.
24. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000;192:1001-14.
25. Nematbakhsh M, Ashrafi F, Pezeshki Z, et al. A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of Cisplatin-induced toxicity in animal model. J Nephropathol. 2012;1:190-3.
26. Gheissari A, Mehrasa P, Merrikhi A, Madihi Y. Acute kidney injury: A pediatric experience over 10 years at a tertiary care center. J Nephropathol. 2012;1:101-8.
27. Tavafi M. Diabetic nephropathy and antioxidants. J Nephropathol. 2013;2:20-7.
28. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002;84:131-41.
29. Cadenas E, Boveris A, Ragan CI, Stoppani AO. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch Biochem Biophys. 1977;180:248-57.
30. Kiritoshi S, Nishikawa T, Sonoda K, et al. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes. 2003;52:2570-7.
31. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57:1446-54.
32. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6:513-9.
33. Morales AI, Detaille D, Prieto M, et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int. 2010;77:861-9.
34. Rafieian-Kopaei M, Nasri H, Nematbakhsh M, Baradaran A, Gheissari A, Rouhi H. Erythropoietin ameliorates genetamycin-induced renal toxicity: A biochemical and histopathological study. J Nephropathol. 2012;1:109-16.
35. Rafieian-Kopaie M, Nasri H. Silymarin and diabetic nephropathy. J Ren Inj Prev. 2012;1: 3-5.
36. Tavafi M. Inhibition of gentamicin-induced renal tubular cell necrosis. J Nephropathol. 2012;1:83-6.
37. Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. 2007;223:86-98.
38. Simmons CF, Jr., Bogusky RT, Humes HD. Inhibitory effects of gentamicin on renal mitochondrial oxidative phosphorylation. J Pharmacol Exp Ther. 1980;214:709-15.
39. Guigas B, Detaille D, Chauvin C, et al. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J. 2004;382:877-84.
40. Amini FG, Rafieian-Kopaei M, Nematbakhsh M, Baradaran A, Nasri H. Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicininduced renal toxicity in Wistar rats. J Res Med Sci 2012;17:621-5.
41. Baradaran A. Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues. J Nephropathol. 2012;1:126-9.
42. Taheri N, Azarmi Y, Neshat M, Garjani A, Doustar Y. Study the effects of metformin on renal function and structure after unilateral ischemia-reperfusion in rat. Research in Pharmaceutical Sciences. 2012;7:274.
43. Assadi F. The epidemic of pediatric chronic kidney disease:the danger of skepticism. J Nephropathol. 2012;1:61-4.
44. Nasri H. Association of serum lipoprotein (a) with hypertension in diabetic patients. Saudi J Kidney Dis Transpl. 2008;19:420-7.
45. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-7.
46. Gheissari A, Hemmatzadeh S, Merrikhi A, Fadaei-Tehrani S, Madihi Y. Chronic kidney disease in children:A report from a tertiary care center over 11 years. J Nephropathol. 2012;1:177-82.
47. Takiyama Y, Harumi T, Watanabe J, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism. Diabetes. 2011;60:981-92.
48. Pavlovic D, Kocic R, Kocic G, et al. Effect of fourweek metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab. 2000;2:251-6.
49. Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, Mansour MA. Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact. 2011;192:233-42.
50. Tolouian R, Hernandez G. Prediction of Diabetic Nephropathy: The need for a sweet biomarker. J Nephropathol. 2013;2:4-5.
51. Puyo AM, Borroni JS, Boudou S, et al. Metformin reduces vascular production of vasoconstrictor prostanoids in fructose overloaded rats. Auton Autacoid Pharmacol. 2012;32:9-14.
52. Rouhi H, Ganji F. Effect of N-acetyl cysteine on serum Lipoprotein (a) and proteinuria in type 2 diabetic patients. J Nephropathol. 2013;1:61-6.
53. Piwkowska A, Rogacka D, Jankowski M, Dominiczak MH, Stepinski JK, Angielski S. Metformin induces suppression of NAD(P)H oxidase activity in podocytes. Biochem Biophys Res Commun. 2010;393:268-73.
54. Ha H, Kim C, Son Y, Chung MH, Kim KH. DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria. Free Radic Biol Med. 1994;16:271-4.
55. Kuchino Y, Mori F, Kasai H, et al. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature. 1987;327:77-9.
56. Merriwether DA, Clark AG, Ballinger SW, et al. The structure of human mitochondrial DNA variation. J Mol Evol. 1991;33:543-55.
57. Suzuki S, Hinokio Y, Komatu K, et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res Clin Pract. 1999;45:161-8.
58. Leinonen J, Lehtimaki T, Toyokuni S, et al. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Lett. 1997;417:150-2.
59. Kim J, Shon E, Kim C, Js JK. Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp Diabetes Res. 2012;21:821.
60. Liu Z, Li J, Zeng Z, Liu M, Wang M. The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, in alloxan-and streptozocin-induced diabetic rats. Chem Biol Interact. 2008;173:68-75.
61. Amador-Licona N, Guizar-Mendoza J, Vargas E, Sanchez-Camargo G, Zamora-Mata L. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res. 2000;31:571-5.
62. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642-6.
63. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004;53:159-64.
64. Raparia K, Usman I, Kanwar YS. Renal morphologic lesions reminiscent of diabetic nephropathy. Arch Pathol Lab Med. 2013;137:351-9.
65. Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? SeminNephrol. 2012;32:452-62.
66. Nasri H. Acute kidney injury and beyond. J Ren Inj Prev. 2012;1:1-2.
67. Rafieian-Kopaei M, Nasri H. Ginger and diabetic nephropathy. J Ren Inj Prev. 2012;2:9-10.
68. Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol. 2011;170:36-47.